melagatran has been researched along with Atherogenesis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bea, F; Blessing, E; Isermann, B; Katus, H; Kreuzer, J; Preusch, M; Rosenfeld, ME; Schaab, S | 1 |
1 other study(ies) available for melagatran and Atherogenesis
Article | Year |
---|---|
Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice.
Topics: Animals; Anticoagulants; Apolipoproteins E; Atherosclerosis; Azetidines; Benzylamines; Carotid Stenosis; Disease Progression; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Hyperlipidemias; Lipids; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Thrombin; Transcription Factor AP-1 | 2006 |